Counterpath Corporation Deferred Share Unit Plan (March 13th, 2017)
Private Placement Subscription Agreement (December 19th, 2016)
The undersigned (the "Subscriber") hereby irrevocably subscribes for and agrees to purchase from CounterPath Corporation (the "Issuer") that number of common shares of the Issuer (each, a "Share") set out below at a price of $2.05 per Share. The Subscriber agrees to be bound by the terms and conditions set forth in the attached "Terms and Conditions of Subscription for Shares".
Counterpath Corporation Deferred Share Unit Plan (December 11th, 2014)
Counterpath Corporation Deferred Share Unit Plan (December 12th, 2013)
Counterpath Corporation & Counterpath Technologies Inc. Settlement Agreement (March 12th, 2009)
CounterPath Corporation a company incorporated under the laws of the state of Nevada and its subsidiary, CounterPath Technologies Inc., a company incorporated under the laws of the Province of British Columbia and both having an office at Suite 300, One Bentall Centre, 505 Burrard Street, Vancouver, British Columbia, Canada V7X1M3 (hereinafter jointly and severely referred to as the "Company")
Escrow Agreement (February 5th, 2008)
COUNTERPATH CORPORATION, a Nevada corporation, with an address at Suite 300, One Bentall Centre, 505 Burrard Street, Vancouver, British Columbia, V7X 1M3
Agreement of Merger and Plan of Reorganization (February 5th, 2008)
THIS AGREEMENT OF MERGER AND PLAN OF REORGANIZATION (this Agreement) is made and entered into on February 1, 2008, by and among COUNTERPATH CORPORATION, a Nevada corporation (Parent), COUNTERPATH ACQUISITION CORP., a Delaware corporation (Acquisition Corp.), which is a wholly-owned subsidiary of Parent, BRIDGEPORT NETWORKS, INC., a Delaware corporation (the Company), POLARIS VENTURE PARTNERS IV, L.P., a limited partnership (Polaris), POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV, L.P., a limited partnership (Polaris Venture), GENERAL CATALYST GROUP II, L.P., a limited partnership (General Catalyst), GC ENTREPRENEURS FUND II, L.P., a limited partnership (GC), TORONTO DOMINION CAPITAL (USA), INC., a corporation (Toronto Dominion) and SUMMERHILL VENTURES I, L.P., a limited partnership (Summerhill).
Contract (June 18th, 2007)
ARRANGEMENT AGREEMENT among: COUNTERPATH SOLUTIONS, INC., a Nevada corporation; 6789722 CANADA INC., a Canada corporation; and NEWHEIGHTS SOFTWARE CORPORATION, a Canadian corporation Dated as of June 15, 2007
Counterpath Solutions R&d, Inc. Employment Agreement (September 14th, 2006)
CounterPath Solutions R&D Inc., a company incorporated under the laws of the Province of British Columbia and having an office at 8th Floor, 100 West Pender Street, Vancouver, British Columbia, Canada V6B1R8.
Chemokine Therapeutics – THIS EXECUTIVE SERVICES AGREEMENT (AGREEMENT) Is Made Effective the 28th Day of June, 2006. JOINTLY BETWEEN: Chemokine Therapeutics Corp. And Chemokine Therapeutics (BC) Corp. 6190 Agronomy Road, Vancouver, BC. Canada V6T 1Z3 (Company) and GUY ELY, MD, (Executive) 2372 Valley Forest Way Oakville, Ontario Canada L6H 6W9 EXECUTIVE SERVICES AGREEMENT (August 10th, 2006)
Company desires to retain Executive through Executives company R.D. Life Sciences Corporation to provide specific medical and drug development services. Executive and Executives company are hereafter together denominated as Executive, unless the context otherwise requires.
Chemokine Therapeutics – Amended Employment Agreement (March 16th, 2005)
THIS AMENDED EMPLOYMENT AGREEMENT is made this 10th day of March 2005 (the Agreement), between Chemokine Therapeutics Corp. a Delaware Corporation and its wholly owned subsidiary Chemokine Therapeutics (B.C.) Corp. a B.C. Corporation (collectively the Company), and David Karp (the Employee or the Executive).
Chemokine Therapeutics – Contract (October 19th, 2004)
EXHIBIT 10.14 Confidential RESEARCH AND DEVELOPMENT AGREEMENT BETWEEN Chemokine Therapeutics Corp. 2386 East Mall Suite 208 Vancouver, B.C. V6T 1Z3 Canada AND Procter & Gamble Pharmaceuticals, Inc. 8700 Mason-Montgomery Road Mason, OH 45040-9462 USA CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR CERTAIN REDACTED PROVISIONS OF THIS AGREEMENT. THE REDACTED PROVISIONS ARE INDICATED BY THREE ASTERISKS ENCLOSED BY BRACKETS AND UNDERLINED. THE CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. WHEREAS: 1. Chemokine Therapeutics, Corp. (hereinafter "CTC") has: a. Proprietary rights and know-how to certain chemokine analogs, including chemokine stromal cell derived factor 1 (SDF-1) and chemokine interleukin 8 (IL-8) analogs as well as other potential chemokine products (agonists and antagonists) t
Chemokine Therapeutics – Contract (August 2nd, 2004)
EXHIBIT 10.5 EMPLOYMENT AGREEMENT THIS AGREEMENT is made as of the 14 day of MAY, 2004. BETWEEN: CHEMOKINE THERAPEUTICS CORP., a Delaware Corporation with its wholly owned subsidiary CHEMOKINE THERAPEUTICS (BC) CORP. a BC Corporation, having a business office at 2386 East Mall, Room 208, Vancouver, BC. V6T 1Z3 (collectively the "Company") AND: DAVID KARP, 3780 BAYRIDGE AVE., WEST VANCOUVER, BC, V7V 3J2 (the "Employee") WHEREAS, A. The Company is engaged in the business of the development of biotechnology products. B. The Employee is presently employed, or is about to be employed, by the Company on the terms and conditions which are now set forth in this Agreement. NOW THEREFORE THIS AGREEMENT WITNESSES that for and in consideration of the Employee's continued employment, the premises and mutual covenants and agreements hereinafter contained, the sum of $1.00 of lawful money o